Intraperitoneal treatment of malignant ascites due to epithelial tumors with catumaxomab: A phase II/III study

被引：1
|
作者：
Parsons, S.
Murawa, P. X.
Koralewski, P.
Kutarska, E.
Kolesnik, O. O.
Stroehlein, M. A.
Lahr, A.
Jaeger, M.
Heiss, M. M.
机构：
[1] City Hosp Nottingham, Nottingham, England
[2] Oddzial Chirurg Onkol, Poznan, Poland
[3] Oddzial Chemioterapii Wojewodzki, Krakow, Poland
[4] Oddzial III Onkol Ginekol, Lublin, Poland
[5] Inst Oncol Acad Med Sci, Kiev, Ukraine
[6] Klinikum Koeln Merheim, Cologne, Germany
[7] Fresenius Biotech GmbH, Munich, Germany
[8] TRION Res GmbH, Martinsried, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3000
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Catumaxomab with and without prednisolone in patients with malignant ascites due to epithelial cancer: Results from the phase IIIb CASIMAS study
    Sehouli, Jalid
    Wimberger, Pauline
    Vergote, Ignace B.
    Rosenberg, Per
    Schneeweiss, Andreas
    Bokemeyer, Carsten
    Salat, Christoph
    Scambia, Giovanni
    Berton-Rigaud, Dominique
    Siena, Salvatore
    Santoro, Armando
    Cervantes-Ruiperez, Andres
    Guastalla, Jean Paul
    Tournigand, Christophe
    Colombo, Nicoletta
    Dudnitchenko, Alexander Serg
    Bondar, Vladimir
    Westermann, A. M.
    Lordick, Florian
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites
    Ott, Marion G.
    Marme, Frederik
    Moldenhauer, Gerhard
    Lindhofer, Horst
    Hennig, Michael
    Spannagl, Rolf
    Essing, Mirko M.
    Linke, Rolf
    Seimetz, Diane
    INTERNATIONAL JOURNAL OF CANCER, 2012, 130 (09) : 2195 - 2203
  • [23] Intraperitoneal Catumaxomab Therapy in a Cirrhotic Patient with Malignant Ascites due to Urethelial Carcinoma: A Case Report
    Krawczyk, Marcin
    Zimmermann, Simone
    Vidacek, Daniel
    Lammert, Frank
    ONKOLOGIE, 2012, 35 (10): : 592 - 594
  • [24] Palliative treatment of malignant ascites: profile of catumaxomab
    Ammouri, Lila
    Prommer, Eric E.
    BIOLOGICS-TARGETS & THERAPY, 2010, 4 : 103 - 110
  • [25] The Role of Relative Lymphocyte Count as a Biomarker for the Effect of Catumaxomab on Survival in Malignant Ascites Patients: Results from a Phase II/III Study
    Heiss, Markus M.
    Stroehlein, Michael A.
    Bokemeyer, Carsten
    Arnold, Dirk
    Parsons, Simon L.
    Seimetz, Diane
    Lindhofer, Horst
    Schulze, Elisabeth
    Hennig, Michael
    CLINICAL CANCER RESEARCH, 2014, 20 (12) : 3348 - 3357
  • [26] Outpatient Intraperitoneal Catumaxomab Therapy for Malignant Ascites Related to Advanced Gynecologic Neoplasms
    Kurbacher, Christian Martin
    Horn, Olympia
    Kurbacher, Jutta Anna
    Herz, Susanne
    Kurbacher, Ann Tabea
    Hildenbrand, Ralf
    Bollmann, Reinhardt
    ONCOLOGIST, 2015, 20 (11): : 1333 - 1341
  • [27] CATUMAXOMAB - A NEW TREATMENT OPTION FOR PATIENTS WITH MALIGNANT ASCITES
    Heiss, M.
    Linke, R.
    Schulze, E.
    Friccius-Quecke, H.
    Hennig, M.
    Gamperl, H.
    Lindhofer, H.
    Parsons, S.
    ANNALS OF ONCOLOGY, 2009, 20 : 12 - 12
  • [28] Catumaxomab in the Treatment of Malignant Ascites: the Evidence of its Therapeutic Value
    Wimberger, Pauline
    Heubner, Martin
    Kimmig, Rainer
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2010, 2 : 481 - 489
  • [29] Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone
    Wimberger, P.
    Gilet, H.
    Gonschior, A-K.
    Heiss, M. M.
    Moehler, M.
    Oskay-Oezcelik, G.
    Al-Batran, S-E.
    Schmalfeldt, B.
    Schmittel, A.
    Schulze, E.
    Parsons, S. L.
    ANNALS OF ONCOLOGY, 2012, 23 (08) : 1979 - 1985
  • [30] The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis
    Stroehlein, Michael A.
    Heiss, Markus M.
    FUTURE ONCOLOGY, 2010, 6 (09) : 1387 - 1394
12345